ESR1 and breast carcinoma: Breast carcinoma cells engineered to overexpress the IGF-1R become resistant to the ER targeting drugs tamoxifen and fulvestrant [139], and xenograft tumors derived from tamoxifen-resistant breast carcinoma cell lines express increased phosphorylated IGF-1R [140].